Psyence Biomedical Ltd. - Ordinary Shares (PBM)

The US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

U.S. futures declined on Friday, ahead of the 'Triple Witching' hour, which is expected to see $6.6 trillion options expire, for the quarter.

Psyence Biomed secures Nasdaq extension to meet compliance by December 31, advancing psilocybin-based therapeutics for mental health treatments.

Psyence Biomed launches Phase IIb trials for psilocybin in palliative care and Alcohol Use Disorder, bolstering its clinical pipeline with key acquisitions and partnerships.